Ocugen, Inc. (OCGN) income statement
OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 1/30
$0.74−0.02 (-2.31%)
Close on Nov 18, 2026Market cap $250.67MP/E –Yield –
Ocugen, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2025
- Gross margin
- –
- Operating margin
- -1561.4%
- Net margin
- -1853.9%
- Return on equity, FY2025
- -776.9%
Financial strength
- Current ratio
- 0.80
- Debt to equity
- -0.11
- Debt to assets
- 1.4%
- Cash to current liabilities
- 75.2%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
See a number that looks wrong?